Immunostimulatory adjuvants, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and toll-like receptor (TLR) ligands are often combined with cancer vaccines, to attract and activate antigen presenting cells (APC) that will take up the cancer vaccines (28). This evidence concerns the gene CSF2 and cancer.